Jun 23, 2010 by Brian Orelli, PhDDuo of Diabetes Drug Deals Make J&J BetterLicensing deals add to its diabetes franchise.
Jun 22, 2010 by Brian Orelli, PhDBetter Late Than Never for MonsantoBiotech alfalfa may be headed to a field near you.
Jun 22, 2010 by Brian Orelli, PhDAn EXELent Bad-News BuyExelixis is more risky, but the 16% drop makes it worth it.
Jun 18, 2010 by Brian Orelli, PhDHot Dog! No Competition for NowRoche's diabetes pipeline drug is delayed.
Jun 16, 2010 by Brian Orelli, PhDA Drop on Bad News, but It Was a Long Shot AnywayBydureon will have a tough time going after the diabetes monotherapy market.
Jun 15, 2010 by Brian Orelli, PhDJust Enough to Give Investors HopeHitting a secondary endpoint means all is not lost for Onyx lung cancer drug.
Jun 15, 2010 by Brian Orelli, PhDMixing It Up With Mixed ResultsA combination of results on combination drugs.
Jun 15, 2010 by Brian Orelli, PhDPfizer Focuses, Investors Should CheerRheumatoid arthritis is no place to be dabbling.
Jun 11, 2010 by Brian Orelli, PhD25 to 0! Now That's a Ringing EndorsementNovartis flies through its advisory panel meeting nearly unscathed.
Jun 11, 2010 by Brian Orelli, PhDDouble-Digit Pop Because the Drug Still Works?Investors may be a little giddy about this one.
Jun 11, 2010 by Brian Orelli, PhDPfizer and Bristol Coagulate Against ClotsLet's see how apixaban does against warfarin before we break out the "blockbuster" stamp.
Jun 10, 2010 by Brian Orelli, PhDCancel the Clowns: Icahn Avoids a CircusThe billionaire investor backs down from a fight.
Jun 10, 2010 by Brian Orelli, PhDPfizer Pforgot What It Learned in KindergartenIt better get with the program, pronto.
Jun 8, 2010 by Brian Orelli, PhDInjecting Uncertainty Into the Multiple Sclerosis MarketNovartis' oral MS drug could be a blockbuster -- if it can get past the FDA.
